Concerns about the accuracy of marketplace information on the viability of a coronavirus treatment product caused the SEC to suspend trading of Aethlon Medical Inc.'s securities Friday.
The information appears to come from third-party promoters who purportedly aren’t affiliated with Aethlon, the Securities and Exchange Commission said. The temporary suspension will last through Feb. 21.
“Unusual market activity” since at least Jan. 22 also prompted the temporary suspension, the agency said. San Diego-based Aethlon is listed on Nasdaq under the symbol AEMD.
An Aethlon representative didn’t immediately respond to a request for comment.
The SEC has been...